The Capital Markets team advised the placement agent in connection with an SEC-registered direct offering by ImmunityBio, Inc. of its common stock and accompanying warrants for aggregate gross proceeds of approximately $50.0 million. The common stock is listed on the Nasdaq Global Select Market under the symbol "IBRX."
ImmunityBio, Inc. is a clinical-stage biotechnology company developing next-generation therapies and vaccines that complement, harness, and amplify the immune system to defeat cancers and infectious diseases.
The Goodwin capital market team consisted of Bryan Quinn, Sebastian Bacon and Joseph Yim. Ora Grinberg provided tax advice. Michael Shuster, Shane Albright and Jennifer Ford provided intellectual property advice. Jacqueline Klosek provided privacy advice. Stephanie Philbin and Emily Tribulski provided FDA advice. Brad Weber provided opinion advice.
For more details, read the press release.